Cover Image
市場調查報告書

急性骨髓性白血病治療的全球市場

Global Acute Myeloid Leukemia Therapeutics Market 2015-2019

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 322190
出版日期 內容資訊 英文 88 Pages
訂單完成後即時交付
價格
Back to Top
急性骨髓性白血病治療的全球市場 Global Acute Myeloid Leukemia Therapeutics Market 2015-2019
出版日期: 2014年12月24日 內容資訊: 英文 88 Pages
簡介

急性骨髓性白血病,是造血幹細胞或造血前驅細胞腫瘤化的造血疾病之一。 腫瘤發生在骨髓,不過,之後在血液中急速蔓延,最後轉移到脾臟、淋巴節、肝臟、腦、脊髓、睪丸等。急性骨髓性白血病治療市場,預計從2014年到2019年的期間,以19.75%的年複合成長率成長。

本報告提供全球急性骨髓性白血病治療市場相關調查分析、市場概要、市場區隔考察、各地區考察、主要企業等相關彙整。

第1章 摘要整理

第2章 簡稱一覽

第3章 報告的範圍

  • 市場概要
  • 商品一覽

第4章 產品簡介

第5章 市場調查的方法

  • 市場調查的流程
  • 調查方法

第6章 簡介

第7章 疾病概要

  • 理解疾病
  • 病因和風險因素
  • 病理學
  • 流行病學
  • 分類
  • 診斷
  • 治療和管理
  • 經濟負擔

第8章 市場的狀況

  • 市場概要
  • 市場的規模與預測
  • 波特的五力分析

第9章 市場區隔:藥物分類

  • 烷化劑
  • 抗腫瘤性抗生素
  • 異構轉化酶抑制劑
  • 其他

第10章 各地區市場區隔

第11章 購買標準

第12章 市場成長的促進要素

第13章 促進要素與其影響

第14章 市場課題

第15章 促進要素與課題的影響

第16章 市場趨勢

第17章 趨勢與其影響

第18章 開發平台的組合

第19章 供應商狀況

  • 競爭模式
  • 市場佔有率分析
  • 其他、今後的主要供應商

第21章 主要供應商分析

  • Bristol Myers Squibb
  • Celgene
  • Johnson and Johnson
  • Pfizer

第23章 本系列的其他報告

目錄
Product Code: IRTNTR4899

About Acute Myeloid Leukemia

Acute myeloid leukemia, also known as acute myelogenous leukemia, is a hematopoietic disorder that starts either in hematopoietic stem cells or lineage-specific progenitor cells. Neoplasms arise from bone marrow, however, it spreads quickly into the blood. In the later stages of the disorder, it spreads to spleen, lymph node, liver, brain, spinal cord and testicles. Clonal expansion of the myeloid blasts and the loss of normal hematopoiesis are the main characteristic of acute myeloid leukemia. The disease affects the elderly people with age of 67 years. Fever, pallor, fatigue and hemorrhages are some of the clinical symptoms of the disease. Smoking, exposure to certain chemicals such as benzene, exposure to radiations, cancer patients, who are treated with chemotherapy, blood disorder or genetic mutations are some of the risk factors for the development of acute myeloid leukemia in patients.

TechNavio's analysts forecast the Global Acute Myeloid Leukemia Therapeutics market to grow at a CAGR of 19.75 percent over the period 2014-2019.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global Acute Myeloid Leukemia Therapeutics market for the period 2015-2019. To calculate the market size, the report considers the revenue generated from the sales of various generic, off-label and branded therapies used for treatment.

The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the Global Acute Myeloid Leukemia Therapeutics market. In addition, the report discusses the major drivers that influence the growth of the market and also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market.

TechNavio's report, Global Acute Myeloid Leukemia Therapeutics Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, the APAC regions and the EMEA regions; it also covers the market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

Key Regions

  • Americas
  • APAC
  • EMEA

Key Vendors

  • Bristol Myers Squibb
  • Celgene
  • Johnson & Johnson
  • Pfizer

Other Prominent Vendors

  • Abbott
  • Ambit BioSciences
  • Amgen
  • Astex Pharmaceuticals
  • AstraZeneca
  • Baxter Healthcare
  • Bayer
  • Boehringer Ingelheim
  • Celator Pharmaceuticals
  • Chroma Therapeutics
  • Chugai Pharmaceutical
  • CTI Biopharma
  • Cyclacel Pharmaceuticals
  • Eisai
  • F. Hoffmann-La Roche
  • Immune Pharmaceuticals
  • Innate Pharma
  • Kanisa Pharmaceuticals
  • Meda
  • Merck Sharp & Dohme
  • Midas Pharmaceuticals
  • Neovii Biotech
  • Nippon Shinyaku
  • Novo Nordisk
  • Sanofi
  • Sunesis Pharmaceuticals
  • Teva Pharmaceutical
  • Tolero Pharmaceuticals

Market Driver

  • Unmet Needs in the Market
  • For a full, detailed list, view our report

Market Challenge

  • Expensive Treatment
  • For a full, detailed list, view our report

Market Trend

  • Expected Entry of Novel Therapies
  • For a full, detailed list, view our report

Key Questions Answered in this Report

  • What will the market size be in 2019 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings

04. Product Profiles

    • 04.1.1. Cytoxan
    • 04.1.2. Vidaza
    • 04.1.3. Dacogen
    • 04.1.4. Idamycin PFS

05. Market Research Methodology

  • 05.1. Market Research Process
  • 05.2. Research Methodology

06. Introduction

07. Disease Overview

  • 07.1. Understanding the Disease
  • 07.2. Etiology and Risk Factors
  • 07.3. Pathophysiology
  • 07.4. Epidemiology
  • 07.5. Classification
    • 07.5.1. FAB Classification
    • 07.5.2. WHO Classification
  • 07.6. Diagnosis
    • 07.6.1. Blood Samples
    • 07.6.2. Bone Marrow Samples
    • 07.6.3. Spinal Fluid
    • 07.6.4. CBC and Peripheral Smear
    • 07.6.5. Blood Chemistry and Coagulation Tests
    • 07.6.6. Microscopic Exams
    • 07.6.7. Cytochemistry
    • 07.6.8. Flow Cytometry and Immunohistochemistry
    • 07.6.9. Cytogenetics
    • 07.6.10. FISH and PCR
    • 07.6.11. X-Ray
    • 07.6.12. CT Scan
    • 07.6.13. Ultrasound
    • 07.6.14. MRI Scan
  • 07.7. Treatment and Management
    • 07.7.1. Induction Therapy
    • 07.7.2. Post Remission Therapy
  • 07.8. Economic Burden

08. Market Landscape

  • 08.1. Market Overview
  • 08.2. Market Size and Forecast
  • 08.3. Five Forces Analysis

09. Market Segmentation by Class of Drugs

  • 09.1. Alkylating Agent
  • 09.2. Cytotoxic Antibiotic
  • 09.3. Topoisomerase Inhibitor
  • 09.4. Others

10. Geographical Segmentation

11. Buying Criteria

12. Market Growth Drivers

13. Drivers and their Impact

14. Market Challenges

15. Impact of Drivers and Challenges

16. Market Trends

17. Trends and their Impact

18. Pipeline Portfolio

19. Vendor Landscape

  • 19.1. Competitive Scenario
    • 19.1.1. Key News
    • 19.1.2. Mergers and Acquisitions
  • 19.2. Market Share Analysis 2014
    • 19.2.1. Celgene
    • 19.2.2. Johnson & Johnson
    • 19.2.3. Pfizer
    • 19.2.4. Bristol Myers Squibb
  • 19.3. Other and Future Prominent Vendors

20. Key Vendor Analysis

  • 20.1. Bristol Myers Squibb
    • 20.1.1. Key Facts
    • 20.1.2. Business Description
    • 20.1.3. Business Segmentation
    • 20.1.4. Revenue by Business Segmentation
    • 20.1.5. Revenue Comparison 2013 and 2014
    • 20.1.6. Sales by Geography
    • 20.1.7. Business Strategy
    • 20.1.8. Key Developments
    • 20.1.9. SWOT Analysis
  • 20.2. Celgene
    • 20.2.1. Key Facts
    • 20.2.2. Business Description
    • 20.2.3. Business Segmentation
    • 20.2.4. Revenue by Business Segmentation
    • 20.2.5. Revenue Comparison 2013 and 2014
    • 20.2.6. Sales by Geography
    • 20.2.7. Business Strategy
    • 20.2.8. Key Developments
    • 20.2.9. SWOT Analysis
  • 20.3. Johnson and Johnson
    • 20.3.1. Key Facts
    • 20.3.2. Business Description
    • 20.3.3. Business Segmentation
    • 20.3.4. Revenue by Business Segmentation
    • 20.3.5. Revenue Comparison 2013 and 2014
    • 20.3.6. Sales by Geography
    • 20.3.7. Business Strategy
    • 20.3.8. Key Developments
    • 20.3.9. SWOT Analysis
  • 20.4. Pfizer
    • 20.4.1. Key Facts
    • 20.4.2. Business Description
    • 20.4.3. Business Segmentation
    • 20.4.4. Revenue by Business Segmentation
    • 20.4.5. Revenue Comparison 2013 and 2014
    • 20.4.6. Sales by Geography
    • 20.4.7. Business Strategy
    • 20.4.8. Key Developments
    • 20.4.9. SWOT Analysis

23. Other Reports in this Series

List of Exhibits

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Snapshot of Acute Myeloid Leukemia
  • Exhibit 3: Percentage of Acute Myeloid Leukemia Cases in Comparison with Other Types of Leukemia in the US 2014
  • Exhibit 4: FAB Classification of Acute Myeloid Leukemia
  • Exhibit 5: FAB Classification of Acute Myeloid Leukemia and the Percentage of Patients in Each Class
  • Exhibit 6: Percentage Distribution of Acute Myeloid Leukemia Patients According to the FAB Classification
  • Exhibit 7: The WHO Classification of Acute Myeloid Leukemia
  • Exhibit 8: Treatment Options for Acute Myeloid Leukemia
  • Exhibit 9: Treatment Options for Relapsed Acute Myeloid Leukemia
  • Exhibit 10: Snapshot of the Economic Burden of Acute Myeloid Leukemia
  • Exhibit 11: Cost Per Patient in Different Treatment Cycles in the US (2012)
  • Exhibit 12: Cost Per Patient in Different Treatment Cycles in the UK (2012)
  • Exhibit 13: Snapshot of the Global Acute Myeloid Leukemia Therapeutics Market, 2014
  • Exhibit 14: Global Acute Myeloid Leukemia Therapeutics Market 2014-2019 (US$ million)
  • Exhibit 15: Global Acute Myeloid Leukemia Therapeutics Market Segmentation by Class of Drugs
  • Exhibit 16: Global Acute Myeloid Leukemia Therapeutics Market Segmentation by Class of Drugs 2014
  • Exhibit 17: Global Acute Myeloid Leukemia Therapeutics Market by Geographical Segmentation 2014
  • Exhibit 18: Buying Criteria of Global Acute Myeloid Leukemia Therapeutics Market
  • Exhibit 19: Phase III Pipeline Molecules for Acute Myeloid Leukemia
  • Exhibit 20: Global Acute Myeloid Leukemia Therapeutics Market Share Analysis 2014
  • Exhibit 21: Authorization Details of Vidaza
  • Exhibit 22: Regulatory History of Dacogen
  • Exhibit 23: Authorization Details of Dacogen
  • Exhibit 24: Bristol-Myers Squibb: Business Segmentation 2014
  • Exhibit 25: Bristol-Myers Squibb: Business Segmentation by Revenue 2013 and 2014 (US$ million)
  • Exhibit 26: Bristol-Myers Squibb: Sales by Geography (in US$ million)
  • Exhibit 27: Celgene: Business Segmentation by Revenue 2013 and 2014
  • Exhibit 28: Celgene: Sales by Geography 2014 (Pharmaceuticals Division)
  • Exhibit 29: Celgene: Sales by Geography 2014 (Diagnostics Division)
  • Exhibit 30: Johnson & Johnson: Business Segmentation by Revenue 2014
  • Exhibit 31: Johnson & Johnson: Business Segmentation by Revenue 2013 and 2014 (US$ million)
  • Exhibit 32: Johnson & Johnson: Sales by Geography 2014
  • Exhibit 33: Pfizer: Business Segmentation
  • Exhibit 19: Pfizer: Revenue by Business Segmentation 2014
  • Exhibit 20: Pfizer: Revenue by Business Segmentation 2013 and 2014 (US$ million)
  • Exhibit 21: Pfizer: Revenue by Geographical Segmentation 2014
Back to Top